ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Invesco Variable Rate Preferred ETF

Invesco Variable Rate Preferred ETF (VRP)

24,27
0,02
(0,08%)
Fermé 25 Janvier 10:00PM
24,27
0,00
(0,00%)
Après les heures de négociation: 10:01PM

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
24,27
Prix Achat
-
Prix Vente
-
Volume échangé
361 036
24,2419 Fourchette du Jour 24,29
23,275 Plage de 52 semaines 24,67
Cap du marché
Clôture Veille
24,25
Ouverture
24,29
Dernière Transaction
4441
@
24.27
Dernière heure de transaction
Volume financier
US$ 8 761 398
VWAP
24,2674
Volume moyen (3 m)
426 332
Actions en circulation
72 100 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
8,75
Bénéfice par action (BPA)
2,77
Chiffre d'affairess
95,49M
Bénéfice net
200,05M

À propos de Invesco Variable Rate Preferred ETF

The investment seeks to track the investment results (before fees and expenses) of the Wells Fargo Hybrid and Preferred Securities Floating and Variable Rate Index. The fund will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is a m... The investment seeks to track the investment results (before fees and expenses) of the Wells Fargo Hybrid and Preferred Securities Floating and Variable Rate Index. The fund will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is a market capitalization-weighted index designed to track the performance of preferred stock, as well as certain types of hybrid securities that are functionally equivalent to preferred stocks, that are issued by U.S.-based or foreign issuers and that pay a floating or variable rate dividend or coupon. It is non-diversified. Show more

Secteur
Mgmt Invt Offices, Open-end
Industrie
Mgmt Invt Offices, Open-end
Site Web
Siège social
Wilmington, Delaware, USA
Fondé
-
Invesco Variable Rate Preferred ETF est coté dans le secteur Mgmt Invt Offices, Open-end de la American Stock Exchange avec le ticker VRP. Le dernier cours de clôture d'Invesco Variable Rate Pr... était de US$24,25. Au cours de la dernière année, les actions de Invesco Variable Rate Pr... ont été négociées dans une fourchette de prix de US$ 23,275 à US$ 24,67.

Invesco Variable Rate Pr... compte actuellement 72 100 000 actions en circulation. La capitalisation boursière d'Invesco Variable Rate Pr... est de US$1,75 milliard. Invesco Variable Rate Pr... a un ratio cours/bénéfice (ratio PE) de 8.75.

VRP Dernières nouvelles

Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases...

CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Verona Pharma plc (Nasdaq: VRNA), please note that all instances of the...

Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

Primary and secondary lung function endpoints met Results support twice-daily dosing LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona...

Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases...

Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference

LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases...

Verona Pharma Announces November 2020 Virtual Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases...

Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020

Initiated ENHANCE Phase 3 clinical trials in COPD Completed $200 million private placement Commenced a pilot clinical study in U.S. patients hospitalized with COVID-19 Conference call today at...

Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update...

LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory...

Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020

LONDON and RALEIGH, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory...

Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

LONDON and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.08-0.32854209445624.3524.3824.261498424.27109632SP
4-0.01-0.041186161449824.2824.461224.0457219724.23014353SP
12-0.14-0.57353543629724.4124.5824.0442633224.34095741SP
260.251.0407993338924.0224.6723.4338556024.269752SP
520.994.2525773195923.2824.6723.27538424824.00649217SP
156-1.35-5.2693208430925.6225.6620.87543474123.17856379SP
260-1.72-6.6179299730725.9926.513.3340339923.74132048SP
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées